leadf
logo-loader
RNS
viewKromek Group PLC

Kromek Group PLC - Kromek CZT technology to improve cancer surgery

RNS Number : 9851B
Kromek Group PLC
14 October 2020
 

This is an RNS Reach announcement and the information contained is not considered to be material or to have a significant impact on management's expectations of the Group's performance. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

14 October 2020

 

Kromek Group plc

("Kromek" or the "Group")

 

Kromek's CZT-based detectors to be used to improve patient outcomes from cancer surgery

New R&D project with Adaptix Ltd and the University of Manchester to enhance pathological medical imaging techniques used during cancer surgery  

 

Kromek (AIM: KMK), a worldwide supplier of detection technology focusing on the medical, security screening and nuclear markets, is pleased to announce that it has commenced development of a new system to improve the pathological medical imaging techniques used during cancer surgery to distinguish between healthy and non-healthy tissue - a new application area for Kromek's technology. The three-year project, which has received grant funding from Innovate UK, is being conducted in partnership with Adaptix Ltd, the developer of a Flat Panel X-ray Source (FPS), and the University of Manchester.   

 

When a cancerous tumour is excised, the surgeon also removes some tissue around the edge of the tumour (the 'margins') to be sure that all the cancer has been removed and is not able to spread. These margins are checked for cancerous tissue while surgery is ongoing using 'pathology cabinets' that provide 2D or 3D images.   

 

The project is to develop a prototype of a new type of pathology cabinet, based on Kromek's CZT detectors and Adaptix's FPS, to produce high-resolution 3D images that provide more accurate differentiation of the boundaries between diseased and healthy tissue. This will enable surgeons to confidently remove the minimum amount of healthy tissue whilst reducing the risk of more than one operation being needed and of cancer spreading from diseased tissue being left after initial surgery. The new system will also be designed to be cost effective and have a small footprint for ease of use in an operating theatre.

 

Kromek's CZT detectors are already incorporated into medical devices used for early detection of diseases such as breast cancer, cardiac conditions and osteoporosis.   

 

Dr Arnab Basu, CEO of Kromek, said: "This is an exciting project for Kromek as it takes our CZT-based detectors into a new application area. Our technology is already being used by leading OEMs to enable the early diagnosis of cancer. With this system, we will contribute to improving the outcome of surgeries through greater image quality. It will reduce the risk of diseased tissue remaining and further surgeries being required while minimising the removal of healthy tissue, which will be of great benefit to both healthcare providers and patients. We look forward to working alongside our partners, Adaptix and the University of Manchester, to complete the development of this new system and take it to the next stage."   

 

 

 

For further information, please contact:

 

Kromek Group plc


Arnab Basu, CEO

Derek Bulmer, CFO

 

+44 (0)1740 626 060

Luther Pendragon (PR)


Harry Chathli

Claire Norbury

Alexis Gore

Joe Quinlan

+44 (0)20 7618 9100

 

 

About Kromek Group plc

 

Kromek Group plc is a technology group (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT") and other advanced technologies. Using its core technology platforms, Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

 

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

 

The Group's business model provides a vertically integrated technology offering to customers, from radiation detector materials to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

 

The Group has operations in the UK and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

 

Currently, the Group has over one hundred full-time employees across its global operations. Further information on Kromek Group is available at www.kromek.com and

https://twitter.com/kromekgroup.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFFMESDESSEES

Quick facts: Kromek Group PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

New Kromek chairman Sir Peter Williams excited by opportunity

Proactive Investors speaks to Sir Peter Williams, science and engineering veteran and newly appointed chairman of Kromek (LON:KMK). Williams, who has also been chairman and chief executive of Oxford Instruments (LON:OXIG), says he hopes to sharpen the commercial and strategic focus of the...

on 09/28/2015

5 min read